New Delhi: Cellworks Research India Ltd, the R&D wing of California based company Cellworks Group Inc which has built systems biology based drug discovery solutions, has successfully helped Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharma company in its ongoing new chemical entity research programme.
Orchid Chemicals & Pharmaceuticals Ltd., is the first India based pharma to adopt system biology technology from Cellworks in order to improve its Drug Discovery efficacy.
Orchid Chemicals and Pharmaceuticals Ltd and Cellworks entered into a collaborative agreement in early 2006 with the objective of incorporating new technologies to New Chemical Entity (NCE) research programme being initiated by Orchid.
Cellworks with its expertise in systems biology leveraged its inflammation in silico platform comprising of various cell types like Macrophage and T-Cell. The aim behind this project was the identification of mechanism of action of key drugs being used in the industry to treat inflammation disorders.
Getting a clear understanding of the underlying drug mechanism and associated toxicities were the driving factors behind this project.
This collaborative research helped in understanding pros and cons of various drug targets and mechanisms. Cellworks technology of automated assertion helped in the identification of key cellular-level bio-markers in the system for each of the drugs individually and in combination and their corresponding implications.
Using cellworks platform of systems biology made it possible to overlay effect of all drugs and visualize how a given biological node or endpoint is affected by different drugs.
According to C Bhaktavatsala Rao,deputy managing director, Orchid Chemicals “We have been closely working with Cellworks solution for key internal drug discovery projects and were able to ascertain which biological receptor targets to focus on . Close collaboration with Cellworks expands our disease biology skills and enables us to deliver better efficacy drugs with contained side-effects”.